Blood thinners increase perioperative complication risk

Article

Use of warfarin or clopidogrel is associated with a significant increase in non-sight-threatening complications during cataract surgery, concluded a study published in the January issue of Eye.

Use of warfarin or clopidogrel is associated with a significant increase in non-sight-threatening complications during cataract surgery, concluded a study published in the January issue of Eye.

Rob L. Johnston, of the Gloucestershire Eye Department, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Cheltenham, Gloucestershire, UK and colleagues remotely used the Cataract National Dataset to extract and analyse data on 48,862 operations for which other pharmaceutical information was available, and assessed how these drugs impacted complication rates. The operations assessed were conducted across eight National Health Service (NHS) centres between 2001 and 2006; 28.1% of the patients studied were taking aspirin, 5.1% were taking warfarin, 1.9% were taking clopidogrel and 1.0% were taking dipyridamole.

The data showed that 8.0% of clopidogrel users reported sharp needle or subtenon’s cannula local anaesthetic block. This compares with 6.2% of warfarin users and 4.3% of other patients. The incidence of sight-threatening complications, however, was similar across all groups. The incidence of subconjunctival haemorrhage was 4.4% for clopidogrel users, 3.7% for warfarin users and 1.7% of other patients. Posterior capsular rupture (PCR) incidence was 3.23% in clopidogrel users and 1.77% for other patients. Overall, 7.3% of clopidogrel users experienced a perioperative complication, compared with 4.4% of other patients.

The researchers concluded that use of either clopidogrel or warfarin increased the likelihood of sharp needle or subtenon’s cannula during cataract surgery, although the risk of sight-threatening or haemorrhagic complications was not increased.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.